BELLUS Health reports results for first half of f...(rotect memory function is based on homot...),Health

Date:8/11/2009

rotect memory function, is based on homotaurine, a naturally occurring ingredient found in certain seaweed. Targeted at healthy baby boomers, this patented natural health brand is expected to address a largely underserved self-care market by providing a scientific, evidence-based health solution. VIVIMIND(TM) is the direct result of over 15 years of significant scientific research, including clinical testing in over 2,000 individuals. Results outlining the beneficial effects of homotaurine were published in the June 2009 edition of the Journal of Nutrition, Health and Aging, the peer-reviewed journal of the European Union Geriatric Medicine Society. They show that homotaurine slows the loss of volume in the hippocampus, a region of the brain associated with memory, and suggest that homotaurine has a beneficial effect on cognition. On the regulatory front, the Company continues to move forward on its original goal of making VIVIMIND(TM) available on a worldwide basis. On July 16, 2009, the Company announced that the Italian Ministry of Health has granted a certificate of free sale for VIVIMIND(TM) as a food supplement, permitting the commercial sale of the product in that country. This certificate opens up means by which to pursue marketing and sales authorization in the other member states of the European Union. With respect to the United States, the Company has filed a premarket notification of a New Dietary Ingredient for homotaurine with the US Food and Drug Administration, and is pursuing mandatory associated regulatory activities to obtain marketing approval for homotaurine as a dietary supplement. Negative net sales for the current periods were attributable to a provision recorded during the current quarter following the Company's decision to reduce VIVIMIND(TM)'s suggested retail price effective July 7, 2009 via announcement to retail customers. This decision is supported by changing economic conditions as well as comments of consumers, healthcare providers a
'/>"/>

SOURCE BELLUS HEALTH INC. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine news :

1. BELLUS Health Inc. Announces $12 Million Rights Offering To Common Shareholders
2. BELLUS Health reports results for first quarter of fiscal 2009
3. BELLUS announces Chief Financial Officer to depart effective May 22, 2009
4. BELLUS Health inc. announces completion of first tranche of financing
5. BELLUS Health reports results for the fourth quarter of 2008
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
7. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
8. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
9. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
10. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
11. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference